Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

37
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
37
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

18
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
18
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.0K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

9.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
9.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Recommendations of the German Society for Rheumatology committee for complementary treatment and nutrition on phytotherapy : Supplement on the use of selected phytotherapeutic agents and herbal preparations in rheumatology: extension to include 13 medicinal plants].

Zeitschrift fur Rheumatologie·2026
Same author

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL).

Rheumatology (Oxford, England)·2026
Same author

Evaluating disease burden in German AAV patients using the AAV-PRO: associations with disease activity, physical function, depression, fatigue and quality of life.

Journal of patient-reported outcomes·2026
Same author

Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)-Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499.

British journal of clinical pharmacology·2026
Same author

New perspectives for better R&D performance: lessons learned from leading pharma companies.

Drug discovery today·2026
Same author

Identifying quality of life domains and facets affected in relapsing polychondritis: a qualitative analysis for the development of a disease-specific health-related quality of life instrument.

Orphanet journal of rare diseases·2026

Related Experiment Video

Updated: Oct 19, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K

A framework to guide dose & regimen strategy for clinical drug development.

Oliver Sander1, Baldur Magnusson1, Inga Ludwig1

  • 1Novartis Pharma AG, Basel, Switzerland.

CPT: Pharmacometrics & Systems Pharmacology
|September 25, 2021
PubMed
Summary

Optimizing drug therapies is complex. This study introduces a new framework to aid clinical development teams in organizing knowledge and fostering collaboration for better treatment decisions.

More Related Videos

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Related Experiment Videos

Last Updated: Oct 19, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Area of Science:

  • Clinical pharmacology
  • Drug development science
  • Quantitative methodologies in medicine

Background:

  • Optimizing new drug therapies presents significant challenges in clinical development.
  • Sophisticated quantitative methodologies are increasingly used but do not fully resolve these challenges.
  • Balancing therapeutic risks and benefits for individual patients requires a multidisciplinary approach.

Purpose of the Study:

  • To present a novel framework designed to enhance knowledge organization.
  • To facilitate improved collaboration among multidisciplinary drug development teams.
  • To address the complexities of personalized medicine and dose optimization.

Main Methods:

  • Development of a conceptual framework for drug development.
  • Focus on knowledge organization and team collaboration strategies.
  • Integration of multidisciplinary insights into a cohesive tool.

Main Results:

  • The proposed framework provides a structured approach to complex drug development problems.
  • It enhances the ability of development teams to organize information effectively.
  • It serves as a tool to facilitate better communication and collaboration.

Conclusions:

  • The presented framework offers a valuable approach to optimizing new drug therapies.
  • It supports multidisciplinary teams in achieving a better risk-benefit balance.
  • This tool can improve the efficiency and effectiveness of clinical development processes.